The FDA has approved a label update for sotatercept (Winrevair) incorporating HYPERION trial data, extending the drug’s clinical evidence base to recently diagnosed pulmonary arterial hypertension patients on background therapy.
The FDA has approved a label update for sotatercept (Winrevair) incorporating HYPERION trial data, extending the drug’s clinical evidence base to recently diagnosed pulmonary arterial hypertension patients on background therapy.
The FDA approved rebisufligene etisparvovec (Fayuvi) on September 17, 2026 — the first therapy cleared to alter the course of Sanfilippo syndrome type A in pediatric patients, giving Ultragenyx its …
AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart — a long-acting interleukin-13 antibody positioned against Dupixent — to its immunology portfolio.
Eli Lilly agreed to acquire Merida Biosciences for up to $2.9 billion, adding a precision antibody-targeting platform to its immunology pipeline as the company’s 2026 acquisition total surpasses $31 billion.
The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for metastatic pancreatic adenocarcinoma, after a phase III trial of 500 patients showed median overall survival of 13.2 months versus 6.7 months …
Positive Phase 2b results for elecoglipron and aleniglipron confirm that small-molecule oral GLP-1 receptor agonists can deliver meaningful weight loss without food or fluid restrictions, intensifying competition in obesity and …
You must be logged in to post a comment.